| 1.35 0.09 (7.14%) | 07-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.73 | 1-year : | 63.41 |
| Resists | First : | 34.02 | Second : | 54.29 |
| Pivot price | 15.04  |
|||
| Supports | First : | 1.23 | Second : | 1.02 |
| MAs | MA(5) : | 21.42 |
MA(20) : | 14.4 |
| MA(100) : | 14.18 |
MA(250) : | 11.38 |
|
| MACD | MACD : | 2.3 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 36.1 |
D(3) : | 36.7 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 54.29 | Low : | 1.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CHRO ] has closed below upper band by 36.4%. Bollinger Bands are 221.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 26.33 - 26.46 | 26.46 - 26.59 |
| Low: | 16.94 - 17.04 | 17.04 - 17.15 |
| Close: | 18.11 - 18.29 | 18.29 - 18.47 |
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Wed, 02 Jul 2025
Ligand announces completion of Pelthos Therapeutics merger with Channel - TipRanks
Fri, 27 Jun 2025
Channel Therapeutics Announces 10-for-1 Reverse Split, $50 Mln Placement - Nasdaq
Fri, 27 Jun 2025
Channel Therapeutics announces 10-for-1 reverse stock split - Investing.com
Fri, 27 Jun 2025
Channel Therapeutics Secures $50M Investment and Merger Deal: What the 10:1 Stock Split Means for Investors - Stock Titan
Fri, 27 Jun 2025
Channel Therapeutics Announces Reverse Common Stock Split - GlobeNewswire
Thu, 01 May 2025
Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 75.5 (%) |
| Held by Institutions | 9.4 (%) |
| Shares Short | 22 (K) |
| Shares Short P.Month | 3 (K) |
| EPS | -1.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -412.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -10.91 |
| PEG Ratio | 0 |
| Price to Book value | -610.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|